August 27, 2014 5:00 PM ET

Healthcare Providers and Services

Company Overview of DiaTech Oncology Corp.

Company Overview

DiaTech Oncology Corp. operates as a clinical pathology laboratory. The company offers the automated kinetic measuring of apoptosis for clinical testing. Its clinical services include drug sensitivity testing of leukemia and lymphoma solid tumor; diagnostic multiparameter flow cytometry analysis; morphologic bone marrow, peripheral blood, and body fluids evaluation; morphologic evaluation for non-hodgkin's and hodgkin's lymphomas, and plasma cell neoplasm; cytogenetics and molecular studies; and diagnostic immunohistochemistry services. DiaTech Oncology Corp. is based in Brentwood, Tennessee with a laboratory location in Montreal, Canada.

9208 Heritage Drive

Brentwood, TN 37027

United States

Phone:

615-377-9668

Fax:

615-665-8730

Key Executives for DiaTech Oncology Corp.

Chief Executive Officer
Chief Medical Officer
Pathology Medical Director and Member of Medical Advisory Board
Compensation as of Fiscal Year 2014.

DiaTech Oncology Corp. Key Developments

DiaTech Oncology to Expand Operations in Franklin, Tennessee

DiaTech Oncology announced the company to expand operations in Franklin, Tennessee. DiaTech's investment of $2.7 million will create 39 new positions over the next two years in Williamson County.

DiaTech Oncology Corp. Receives Clinical Laboratory Permit from New York State Department Of Health

DiaTech Oncology Corp. announced that the company has received a Clinical Laboratory Permit from the New York State Department Of Health. DiaTech's predictive assay test - which guides the treating oncologist to the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient - is now available to patients and physicians in all 50 states.

DiaTech Oncology Corp. Receives New York State Clinical Laboratory Permit for Predictive Assay Test

DiaTech Oncology Corp. announced that the company has received a Clinical Laboratory Permit from the New York State Department of Health (NYS DOH). DiaTech's predictive assay test -- which guides the treating oncologist to the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient -- is now available to patients and physicians in all 50 states. In clinical trials and published research, use of DiaTech Oncology's test -- the MiCK(R) assay or Correct Chemo(R) -- has consistently shown an increase in complete or partial response rates, longer time to relapse and a trend to longer survival times for more than 50 types of cancers, including lung, breast, colorectal, stomach, prostate, liver, ovarian, esophageal, bladder, non-Hodgkin lymphoma, leukemia and other cancers.

Similar Private Companies By Industry

Company Name Region
HC Healthcare, Inc. United States
Saratoga Equine: A Rood & Riddle Hospital United States
Clinical Associates, Inc. United States
Mid-America Diabetes Associates, P.A. United States
EndoSolutions, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DiaTech Oncology Corp., please visit www.diatech-oncology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.